Merck & Co.
Public MRK · United States
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
15 approved
18 in Phase 3
Drugs
68
in active trials · 197 in all
Trials
228 active
770 since 2021
Drugs68
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-1 antibody |
Approved | 20 Nov 2026soonPhase 3 trial completes | |||
| Next date | 20 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Melanoma and 251 more | ||||
| Open drug page | |||||
TROP2-targeted antibody-drug conjugate |
Kelun-Biotech |
Approved in China | Nov 2026soonPhase 3 trial completes | ||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC) and 38 more | ||||
| Open drug page | |||||
Hypoxia-inducible factor inhibitor |
Approved | 22 Dec 2026Phase 1/2 trial completes | |||
| Next date | 22 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Renal Cell Carcinoma, Carcinoma, Renal Cell and 39 more | ||||
| Open drug page | |||||
— |
Approved | 15 Jan 2027Phase 3 trial completes | |||
| Next date | 15 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Papillomavirus Infections, Genital Warts | ||||
| Open drug page | |||||
Kinase inhibitor |
Eisai |
Approved | 22 Mar 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 22 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Renal Cell, Renal Cell Carcinoma and 14 more | ||||
| Open drug page | |||||
Azole antifungal |
Approved | 31 Mar 2027Phase 2 trial completes | |||
| Next date | 31 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Invasive Fungal Infection | ||||
| Open drug page | |||||
Orexin receptor antagonist |
Approved | 24 Jun 2027Phase 3 trial completes | |||
| Next date | 24 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Insomnia | ||||
| Open drug page | |||||
— |
Approved | 12 Oct 2027Phase 2 trial completes | |||
| Next date | 12 Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Hypercholesterolemia, Hyperlipidemia and 4 more | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | 21 Mar 2028Phase 4 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | 21 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | Pulmonary Arterial Hypertension, Hypertension, Pulmonary and 1 more | ||||
| Open drug page | |||||
— |
Approved | 31 Mar 2028Phase 3 trial completes | |||
| Next date | 31 Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Papillomavirus Infections | ||||
| Open drug page | |||||
Cytomegalovirus DNA terminase complex inhibitor |
Approved | 14 Apr 2028Phase 1 trial completes | |||
| Next date | 14 Apr 2028 · Phase 1 trial completes | ||||
| Also tested for | Cytomegalovirus Prophylaxis | ||||
| Open drug page | |||||
Human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor |
Approved | 12 Nov 2028Phase 2 trial completes | |||
| Next date | 12 Nov 2028 · Phase 2 trial completes | ||||
| Also tested for | Human Immunodeficiency Virus (HIV) Infection | ||||
| Open drug page | |||||
— |
Approved | 29 May 2029Phase 3 trial completes | |||
| Next date | 29 May 2029 · Phase 3 trial completes | ||||
| Also tested for | HIV-1 Infection, HIV Infection and 1 more | ||||
| Open drug page | |||||
Soluble guanylate cyclase stimulator |
Approved | 20 Aug 2029Phase 2/3 trial completes | |||
| How it works | Boosts a chemical signal (cGMP) that relaxes blood vessels and eases strain on the heart | ||||
| Next date | 20 Aug 2029 · Phase 2/3 trial completes | ||||
| Also tested for | Heart Failure, Left Ventricular Systolic Dysfunction | ||||
| Open drug page | |||||
— |
Approved in other | 26 Jan 2031Phase 3 trial completes | |||
| Next date | 26 Jan 2031 · Phase 3 trial completes | ||||
| Also tested for | Coronavirus Disease (COVID-19) | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 3 | 17 Feb 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 17 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease and 10 more | ||||
| Open drug page | |||||
Personalised mRNA cancer vaccine |
Moderna |
Phase 3 | 23 Apr 2027Phase 1/2 trial completes | ||
| Next date | 23 Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Melanoma, Non-small Cell Lung Cancer and 9 more | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Phase 3 | 19 May 2027Phase 3 trial completes | |||
| How it works | Blocks BTK | ||||
| Next date | 19 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 20 more | ||||
| Open drug page | |||||
— |
Phase 3 | 14 Jul 2027Phase 3 trial completes | |||
| Next date | 14 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Essential Thrombocythemia, Polycythemia Vera and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | 22 Jul 2027Phase 3 trial completes | |||
| Next date | 22 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings25
Since Feb 2024 · All on SEC.gov- 29 OctReported quarterly results · SEC 8-K
- 13 OctChanged a director or officer · SEC 8-K
- 4 AugReported quarterly results · SEC 8-K
- 28 MayFiled a report · SEC 8-K
- 22 MayReported other events · SEC 8-K
- 18–20 MayOffered new securities · 2 prospectuses (424B5)
- 30 AprReported quarterly results · SEC 8-K
- 3 FebReported quarterly results · SEC 8-K
- 4 Dec 2025Reported other events · SEC 8-K
- 1–3 Dec 2025Offered new securities · 2 prospectuses (424B5)
- 30 Oct 2025Reported quarterly results · SEC 8-K
- 9 Sep 2025Reported other events · SEC 8-K
- 2–4 Sep 2025Offered new securities · 2 prospectuses (424B5)
- 29 Jul 2025Reported quarterly results · SEC 8-K
- 29 May 2025Filed a report · SEC 8-K
- 24 Apr 2025Reported quarterly results · SEC 8-K
- 4 Feb 2025Reported quarterly results · SEC 8-K
- 22 Nov 2024Changed a director or officer · SEC 8-K
- 31 Oct 2024Reported quarterly results · SEC 8-K
- 30 Jul 2024Reported quarterly results · SEC 8-K
- 30 May 2024Reported other events · SEC 8-K
- 15–20 May 2024Offered new securities · 2 prospectuses (424B5)
- 25 Apr 2024Reported quarterly results · SEC 8-K
- 20 Feb 2024Changed a director or officer · SEC 8-K
- 1 Feb 2024Reported quarterly results · SEC 8-K
About
- No active trial
- 129 other drugs
- Registry names
- 2 names in ClinicalTrials.gov Merck Sharp & Dohme LLC
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev